Eli Lilly Strikes $2.75 Billion Deal With AI Drug Pioneer Insilico Medicine to Fast-Track Global Drug Development
Summary
Eli Lilly signs a landmark $2.75 billion deal with AI drug pioneer Insilico Medicine, offering $115 million upfront to fast-track AI-generated drugs across multiple disease areas into global markets.
Key Points
- Eli Lilly strikes a $2.75 billion deal with Hong Kong-based Insilico Medicine to bring AI-developed drugs to the global market, with Insilico receiving $115 million upfront and the rest tied to regulatory and commercial milestones.
- Insilico Medicine, which went public in Hong Kong in December and has seen its shares surge over 50% year-to-date, has developed at least 28 drugs using generative AI, with nearly half already in clinical stages.
- The partnership, rooted in a 2023 AI software licensing agreement, aims to accelerate drug discovery across multiple disease areas, with Insilico joining Lilly's Gateway Labs biotech development community as part of the expanded deal.